AbbVie, Inc.

AbbVie, Inc. has faced notable volatility, with a significant stock decline today and a downward trend over the past week and month. Despite a positive three-year performance, its one-year return is negative. Financial metrics reveal a high debt-to-equity ratio and low inventory turnover, raising concerns about long-term stability.

AbbVie, Inc. opened with a notable decline, continuing a downward trend over the past month. The company's market capitalization is around USD 399 billion, with a P/E ratio of 38.00 and a dividend yield of 2.94%. Technical indicators present mixed signals regarding its market outlook.

AbbVie, Inc. faced a notable stock decline, reaching an intraday low and reflecting a challenging trading environment. The company has experienced significant decreases over the past week and month, with high debt levels and low inventory turnover raising concerns about its long-term stability despite previous performance gains.

AbbVie, Inc. faced a notable decline in its stock price, reaching an intraday low during a challenging trading session. The company has experienced significant decreases over the past week and month, with financial metrics indicating pressures, including a high debt-to-equity ratio and substantial quarterly interest expenses.

AbbVie, Inc., a major player in the Pharmaceuticals & Biotechnology sector, has demonstrated strong performance metrics, including notable stock returns that surpass the S&P 500 over various time frames. The company's recent trading activity and technical indicators reflect a complex market position, emphasizing its competitive resilience.

AbbVie, Inc. has demonstrated strong stock performance, gaining 3.29% on February 27, 2026, and reaching an intraday high of USD 232.27. Over the past month, the stock has increased by 3.64%, contrasting with the S&P 500's decline. AbbVie maintains a market cap of approximately USD 404.96 billion.

AbbVie, Inc., a major player in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise to $232.08, reflecting a significant range in performance over the past year. The company has demonstrated resilience compared to the S&P 500, achieving notable returns over both one and three-year periods.

AbbVie, Inc. has achieved a new 52-week high, reflecting a strong performance with a notable increase over the past year. The company, with a market capitalization of USD 377,734 million, features a P/E ratio of 23.00 and a high dividend yield, despite some concerning financial metrics.

AbbVie, Inc. has achieved a new 52-week high, reflecting strong performance with a notable increase over the past year. The company, with a market capitalization of approximately USD 377.73 billion, features a P/E ratio of 23.00 and a substantial dividend yield, despite challenges in return on equity and debt-equity ratio.

AbbVie, Inc. has seen a notable increase in its stock performance today, contrasting with the modest rise of the S&P 500. Over the past week and month, AbbVie has outperformed the index significantly. However, concerns remain regarding its high debt burden and weak long-term fundamentals.

AbbVie, Inc. achieved a new 52-week high of USD 225.16 on September 22, 2025, reflecting a strong performance with a 30.58% increase over the past year. The company, with a market cap of approximately USD 377.73 billion, faces challenges with a negative return on equity despite its notable dividend yield.

AbbVie, Inc. has achieved a new 52-week high, reflecting strong performance with a notable increase over the past year. The company, with a market capitalization of USD 377.73 billion, features a P/E ratio of 23.00 and a high dividend yield, despite reporting a negative return on equity.

AbbVie, Inc. has achieved a new 52-week high of USD 222.07, reflecting a strong performance with a 30.23% increase over the past year. The company, with a market capitalization of USD 377,734 million, features a P/E ratio of 23.00 and a notable dividend yield of 150.59%.